• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • NORTH AMERICA EDITION
      Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • NORTH AMERICA EDITION
      North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Biotech Market
    Biotech News
    Biotech Stocks
    • Biotech Market
    • Biotech News
    • Biotech Stocks

    Nexvet to Present at the 25th Annual Credit Suisse Healthcare Conference

    Chelsea Pratt
    Oct. 19, 2016 02:49AM PST
    Biotech Investing

    Nexvet Biopharma, a veterinary biologic therapy developer, today announced that its Chief Executive Officer, Dr. Mark Heffernan, is scheduled to present at the 25th Annual Credit Suisse Healthcare Conference.

    Nexvet Biopharma (Nasdaq:NVET), a veterinary biologic therapy developer, today announced that its Chief Executive Officer, Dr. Mark Heffernan, is scheduled to present at the 25th Annual Credit Suisse Healthcare Conference in Scottsdale, AZ on Monday, November 7th at 11:00AM MT.

    Dr. Heffernan will provide an overview of Nexvet’s pivotal-stage clinical programs for chronic pain in cats and dogs, as well as its therapies in development in the areas of immuno-oncology, inflammation, and allergy.
    The presentation will be available on the investor section of Nexvet’s website at https://ir.nexvet.com following the completion of the event.

    About Nexvet (www.nexvet.com)

    Nexvet is a veterinary biologic therapeutics company focused on transforming the therapeutic market for companion animals, such as dogs and cats, by developing and commercializing novel, species-specific biologics. Nexvet’s proprietary PETization™ platform is designed to rapidly design monoclonal antibodies (mAbs) that are recognized as “self” or “native” by an animal’s immune system, a property Nexvet refers to as “100% species-specificity.” Nexvet’s product candidates build upon the safety and efficacy data from clinically tested human therapies, thereby reducing clinical risk and development cost.
    Nexvet is leveraging diverse global expertise and incentives to build a vertically integrated biopharmaceutical company, which conducts drug discovery in Australia, conducts clinical development in the United States and Europe and conducts biomanufacturing in Ireland.

    Further information:

    Investors                                                                      
    Candice Knoll
    Blueprint Life Science Group
    +1 415-375-3340 Ext. 4
    cknoll@bplifescience.com

    Media
    Jessica Burns
    Berry & Company Public Relations
    +1 212-253-8881
    jburns@berrypr.com

    australianexveteuropecredit suissehealthcare conference
    The Conversation (0)

    Go Deeper

    AI Powered
    Senior woman doing exercises alongside closeup of DNA.

    5 US Longevity and Anti-aging Stocks to Watch in 2025

    Large pharmaceutical pill with gold dollar sign in the middle. Stock tickers and charts in the background.

    Top 5 Small-cap Pharma Stocks of 2025

    Latest News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Biotech Investing Stocks

    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×